Sign In
Buy IMAB
$4.63
+0 (+0%)
At Close: Apr 14, 2026
I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health
07:00am, Thursday, 17'th Jul 2025
ROCKVILLE, Md., July 17, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treat
Data show confirmed ORR of 83% (10/12) at doses selected for ongoing expansion study Median follow-up of 9.0 months as of the updated data cutoff Responses observed in patients with low PD-L1 and/or C
I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research
04:01pm, Monday, 30'th Jun 2025
Monotherapy efficacy and safety profile provided backbone for clinical development strategy in 1L combination with nivolumab plus chemotherapy
71% objective response rate (ORR) (12/17) per RECIST v1.1, with a favorable safety profile 83% ORR (10/12) in patients across doses selected for ongoing dose expansion study Responses observed in pati
I-Mab Sponsored ADR (IMAB)'s Technical Outlook is Bright After Key Golden Cross
10:56am, Wednesday, 11'th Jun 2025
I-Mab Sponsored ADR (IMAB) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, IMAB's 50-day simple moving average crossed above
I-Mab Sponsored ADR (IMAB) is a Great Momentum Stock: Should You Buy?
01:01pm, Friday, 06'th Jun 2025
Does I-Mab Sponsored ADR (IMAB) have what it takes to be a top stock pick for momentum investors? Let's find out.
I-Mab to Present at Jefferies Global Healthcare Conference
07:00am, Tuesday, 20'th May 2025
ROCKVILLE, Md., May 20, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the
After Plunging -20.33% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB)
10:35am, Monday, 14'th Apr 2025
The heavy selling pressure might have exhausted for IMab (IMAB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in re
After Plunging -19.7% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB)
10:35am, Friday, 11'th Apr 2025
The heavy selling pressure might have exhausted for IMab (IMAB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in re
I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
04:30pm, Friday, 21'st Mar 2025
ROCKVILLE, Md., March 21, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (“I-Mab” or the “Company”), announced today that on March 19, 2025 it received a written notice (the “Notice”) from
I-Mab Announces Accelerated Givastomig Phase 1b Study Progress
07:00am, Friday, 07'th Mar 2025
ROCKVILLE, Md., March 07, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for th
I-Mab to Participate in Leerink Partners Global Healthcare Conference
07:00am, Tuesday, 18'th Feb 2025
ROCKVILLE, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a US-based, global biotech company, exclusively focused on the development of precision immune-oncology agen
I-Mab to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference
07:30am, Tuesday, 04'th Feb 2025
ROCKVILLE, Md., Feb. 04, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treat
I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member
07:00am, Wednesday, 08'th Jan 2025
Chairman of the Board, Wei Fu, informed the Company of his intent to purchase up to $2,000,000 of the Company's American Depository Shares (ADSs) ROCKVILLE, Md. , Jan. 8, 2025 /PRNewswire/ -- I-Mab (N
I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program
07:00am, Monday, 06'th Jan 2025
Givastomig: a Claudin 18.2 ("CLDN18.2") x 4-1BB bispecific antibody, will be the lead clinical program following the Company's portfolio prioritization The Company has completed enrollment of a dose e
